linjc16/ctgov huggingface dataset:
Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital

Study Overview
=================
Brief Summary
-----------------
This Research is compare about IV Calcium between end-stage renal failure patients who take vitamin D and non-vitamin D preoperative parathyroidectomy

Official Title
-----------------
Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Drug: Calcitriol
* Drug: Alfacalcidol 0.5 MCG Oral Capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: New End-stage renal failure patients and have iPTH>800 pg/dl at least 6 months Patients who no response hyperphosphatemia with high dose vitamin D Exclusion Criteria: Allergy vitamin D Pregnancy Patients who parathyroidectomy have less than 4 gland

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: take calcitriol<br>End-stage renal failure patients who is Hyperparathyroid with ESRD take calcitriol | Drug: Calcitriol<br>* end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy<br>|
| Experimental: take alphacalcidol<br>End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol) | Drug: Alfacalcidol 0.5 MCG Oral Capsule<br>* end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy<br>|
| No Intervention: control<br>End-stage renal failure patients who is Hyperparathyroid with ESRD take standard treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of serum calcium level between patients who take Vitamin D and non-Vitamin D | Comparison of serum calcium level between patients who take Vitamin D and non-Vitamin D | 4 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypocalcemia, Hyperparathyroidism, End Stage Renal Disease (ESRD), calcitriol
Sleep and Daytime Activity in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Sleep relate to cognitive function.

Conditions
-----------------
Cognitive Function

Intervention / Treatment
-----------------
* Behavioral: sleep


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy Exclusion Criteria: patients

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: sleep|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Study Overview
=================
Brief Summary
-----------------
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or intolerant of current antiretroviral regimen and who are unable to swallow Sustiva capsules.

Official Title
-----------------
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)

Conditions
-----------------
HIV Infection

Intervention / Treatment
-----------------
* Drug: Efavirenz


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 3-16 years of age Anti-retroviral naive or experienced Failing or intolerant to current Anti-retroviral regimen Limited available viable therapeutic options Inability to take capsules/tablets Exclusion Criteria: Less than 10kg Failure on or concomitant use of other NNRTIs An active AIDS-defining opportunistic infection or disease More than two episodes of moderate to severe diarrhea or vomiting lasting more than four days within the past three months

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Experimental Study of Detection an Intentional Performance Degradation in Grip Strength

Study Overview
=================
Brief Summary
-----------------
In this study, the detection of the feigning weakness in grip strength is measured using different grip strength testing instruments. Patients with injury of the upper limb are compared to patients with injury of the lower limb as well as healthy controls.

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - >18 years, signed consent form, stable pain mediaction for 48 hours Exclusion Criteria: - <18, unsigned consent form, dose change of the pain medication during the last 48 hours...

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy<br>> 18 years old sufficient language knowledge | |
| chronic pain patients<br> | |
| patients with injury at the upper etxremity<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| grip strength | mean and maximum grip strength measured by rapid exchange grip and isometric grip strength testing | 1 hour | 
| range of motion | measured by the handtutor | 1 hour |
Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome

Study Overview
=================
Brief Summary
-----------------
This study addresses the changes in the axonal excitability parameters. It will compare these changes in patients with early infantile epileptic encephalopathy with HCN1 channel mutation and in control patients, with and without epilepsy.

Official Title
-----------------
Neuronal Excitability of Hyperpolarization-activated Cyclic Nucleotide-gated (HCN1) Channel Mutations in Dravet Syndrome

Conditions
-----------------
Dravet Syndrome

Intervention / Treatment
-----------------
* Device: measure of neuronal excitability


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: early infantile epileptic encephalopathy with HCN1 channel mutation control patients with no neurologic pathology (age, gender and body temperature matched) epileptic patients (age, gender and body temperature matched) Exclusion Criteria: pregnant or breast feeding patient

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dravet syndrome - HCN1 channel mutation<br>early infantile epileptic encephalopathy with HCN1 channel mutation | Device: measure of neuronal excitability<br> <br> |
| control with epilepsy<br> | Device: measure of neuronal excitability<br> <br> |
| control without epilepsy<br> | Device: measure of neuronal excitability<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hyperpolarizing electrotonus |  | baseline | 
| hyperpolarizing threshold current |  | baseline |
Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
Study of Oxidative stress Markers (F2 Isoprostanes for lipid peroxidation, Carbonyl groups for protein peroxidation, 3 Nitrotyrosine for damage by nitrogens, and 8-Hydroxyguanosine for RNA peroxidation)in patients with colorectal cancer undergo surgical treatment (preoperatively during the intervention and postoperatively) and controls.

Detailed Description
-----------------
Study of the impact of surgery on Lipid peroxidation, Protein peroxidation, damage by nitrogens, and RNA peroxidation, in patients undergo surgical resection for colorectal cancer and compared with controls, and validation of the responsiveness of oxidative stress markers on surgery

Official Title
-----------------
Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer

Conditions
-----------------
Colorectal Cancer, Colon Rectal Resection, Oxidative Stress

Intervention / Treatment
-----------------
* Procedure: Surgery for colorectal cancer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with colorectal cancer Controls Exclusion Criteria: ASA>3 Metastatic Disease Acute bowel obstruction Acute bowel perforation BMI<30 Chronic Systemic or Autoimmune Diseases Smokers Alcohol consumers

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Surgery for colorectal cancer<br>Colorectal cancer patients | Procedure: Surgery for colorectal cancer<br>* Surgical resection of colorectal cancer<br>* Other names: Right colectomy;|
| No Intervention: Controls<br>Controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of Oxidative stress markers in patients with colorectal cancer and controls | Oxidative stress markers variation (8-PGF2α, Protein Carboyls, 3-Nitrotyrosine, 8-OHG) during and after surgery for colorectal cancer, and compare with controls | up to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of oxidative stress markers in patients with colorectal cancer undergo surgical resection | Validation of the responsiveness of markers of oxidative stress 8-PGF2α, Protein Carboyls, 3-Nitrotyrosine, 8-OHG)on surgery | up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal cancer, Surgical resection, Oxidative Stress Markers, Controls
Ocular Changes in Vitiligo Patients on Therapy

Study Overview
=================
Brief Summary
-----------------
Vitiligo patients on systemic and local therapy may have some ocular adverse effects associated with the disease and its therapy.

Detailed Description
-----------------
Chorioretinal changes associated with vitiligo therapy could address patients visual acuity and life style. Early detection of these changes can help these patients to evade such adverse effects.

Official Title
-----------------
Chorioretinal Changes in Vitiligo Patients on Therapy

Conditions
-----------------
Vitiligo, Chorioretinopathy, Chorioretinitis

Intervention / Treatment
-----------------
* Diagnostic Test: Optical coherence tomography angiography (OCT-A)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: vitiligo patients on systemic and local therapy that regularly visit dermatology clinic at banha university. normal subjects seeking regular ophthalmic examination at ophthalmology clinic at banha university. Exclusion Criteria: patients with known chronic retinal diseases that may alter OCT-A parameters as age related macular degeneration and diabetic retinopathies. patients that refuse to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Vitiligo patients on therapy<br>Patients diagnosed as vitiligo and on systemic and local therapy. | Diagnostic Test: Optical coherence tomography angiography (OCT-A)<br>* Optical coherence tomography angiography scanning will be done for all subjects in the study.<br>* Other names: OCT-A;|
| Control group<br>Normal subjects recruited from ophthalmology clinic and visit the clinic for regular check-up. | Diagnostic Test: Optical coherence tomography angiography (OCT-A)<br>* Optical coherence tomography angiography scanning will be done for all subjects in the study.<br>* Other names: OCT-A;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of vessel density (VD) in superficial and deep retinal layer. | Percentage (%) of superficial and deep vessel density changes in both groups measured by OCT-A software to asses retinal ischemia. | Immediately after OCT-A for each eye and at one month of follow-up. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Foveal avascular zone (FAZ) in millimeter (mm). | Foveal avascular zone measurement in both groups in mm measured by OCT-A software. | Immediately after OCT-A for each eye and at one month of follow-up. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitiligo, Chorioretinitis
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.

Detailed Description
-----------------
This is a dose-finding study to select a safe and efficacious dose of OPT-80. Patients will be evaluated for safety and efficacy and pharmacokinetic parameters will be investigated.

Official Title
-----------------
An Open-Label, Dose Ranging, Randomized Clinical Evaluation of OPT-80 in Patients With Clostridium Difficile-Associated Diarrhea (CDAD)

Conditions
-----------------
Diarrhea

Intervention / Treatment
-----------------
* Drug: OPT-80


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with CDAD Exclusion Criteria: Patients with severe CDAD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: OPT-80|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relief of symptoms of CDAD |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence Rate. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CDAD, diarrhea, Clostridium difficile-Associated Diarrhea
Chronic Rhinosinusitis: Biochemical Markers and Biofilm

Study Overview
=================
Brief Summary
-----------------
The investigators will conduct a descriptive, prospective, three-armed study concerning the pathophysiology of chronic rhinosinusitis. In one part of the study the investigators want to investigate the presence of biofilm in patients with chronic rhinosinusitis both with and without nasal polyps compared with a control group of subjects without chronic rhinosinusitis. The investigators will also compare quality of life in the three groups and correlate disease severity in biofilm patients versus patients where biofilm was not present. The hypothesis here is that biofilm patients suffers a more severe disease. In the other arm of the study the investigators will compare the presence of different biochemical compounds in the three study groups. The investigators specifically want to investigate matrix metalloproteases and apoptosis-inhibitors with immunohistochemistry. The investigators may also add other compounds to our test-battery if interesting candidates surface in the literature during the inclusion period. The purpose of this part of the study is to investigate candidates for the development of nasal polyposis. The investigators plan to include 100 patients suffering from chronic rhinosinusitis with nasal polyps, and 100 patients with chronic rhinosinusitis without nasal polyps and 30 control subjects.

Conditions
-----------------
Chronic Rhinosinusitis

Intervention / Treatment
-----------------
* Procedure: biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of chronic rhinosinusitis based on EPOS3 Submitted to surgery Using nasal corticosteroids Exclusion Criteria: Age below 18 years Using antibiotics at the time of surgery Using systemic corticosteroids Sempers triad

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic rhinosinusitis with nasal polyps<br> | Procedure: biopsy<br>* One or more biopsies from nasal mucosa will be harvested during surgery<br>|
| chronic rhinosinusitis without nasal polyps<br> | Procedure: biopsy<br>* One or more biopsies from nasal mucosa will be harvested during surgery<br>|
| Control group<br> | Procedure: biopsy<br>* One or more biopsies from nasal mucosa will be harvested during surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1

Conditions
-----------------
Hepatorenal Syndrome

Intervention / Treatment
-----------------
* Drug: terlipressin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic, or acute liver disease Rapidly progressive reduction in renal function, e.g. doubling of serum creatinine to >2.5 mg/dL in less than two weeks. No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion Proteinuria <500 mg per day No evidence of granular casts in urinalysis or ultrasonographic evidence of obstructive uropathy or parenchymal renal disease Exclusion Criteria: Ongoing shock Uncontrolled bacterial infection Current significant fluid losses Current or recent treatment with nephrotoxic drugs (e.g. NSAIDs or aminoglycosides within 4 weeks) Acute liver disease due to factors known to be also directly nephrotoxic (e.g. acetaminophen overdose) Confirmed pregnancy Severe cardiovascular disease Evidence of intrinsic or parenchymal renal disease (e.g. acute tubular necrosis) Participation in other clinical studies within 30 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Terlipressin<br>Terlipressin | Drug: terlipressin<br> <br> |
| Placebo Comparator: Placebo<br>Placebo | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment Success |  | Day 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function and survival |  | Renal funtion to Day 14 and Survival to Day 180 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatorenal syndrome, terlipressin